A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

Lisa H Butterfield, Mary L Disis, Bernard A Fox, Peter P Lee, Samir N Khleif, Magdalena Thurin, Giorgio Trinchieri, Ena Wang, Jon Wigginton, Damien Chaussabel, George Coukos, Madhav Dhodapkar, Leif Håkansson, Sylvia Janetzki, Thomas O Kleen, John M Kirkwood, Cristina Maccalli, Holden Maecker, Michele Maio, Anatoli Malyguine, Giuseppe Masucci, A Karolina Palucka, Douglas M Potter, Antoni Ribas, Licia Rivoltini, Dolores Schendel, Barbara Seliger, Senthamil Selvan, Craig L Slingluff Jr, David F Stroncek, Howard Streicher, Xifeng Wu, Benjamin Zeskind, Yingdong Zhao, Mai-Britt Zocca, Heinz Zwierzina, Francesco M Marincola, Lisa H Butterfield, Mary L Disis, Bernard A Fox, Peter P Lee, Samir N Khleif, Magdalena Thurin, Giorgio Trinchieri, Ena Wang, Jon Wigginton, Damien Chaussabel, George Coukos, Madhav Dhodapkar, Leif Håkansson, Sylvia Janetzki, Thomas O Kleen, John M Kirkwood, Cristina Maccalli, Holden Maecker, Michele Maio, Anatoli Malyguine, Giuseppe Masucci, A Karolina Palucka, Douglas M Potter, Antoni Ribas, Licia Rivoltini, Dolores Schendel, Barbara Seliger, Senthamil Selvan, Craig L Slingluff Jr, David F Stroncek, Howard Streicher, Xifeng Wu, Benjamin Zeskind, Yingdong Zhao, Mai-Britt Zocca, Heinz Zwierzina, Francesco M Marincola

Abstract

The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for the identification of relevant parameters to assist clinical and basic scientists who study the natural course of host/tumor interactions or their response to immune manipulation. The task force has two primary goals: 1) identify best practices of standardized and validated immune monitoring procedures and assays to promote inter-trial comparisons and 2) develop strategies for the identification of novel biomarkers that may enhance our understating of principles governing human cancer immune biology and, consequently, implement their clinical application. Two working groups were created that will report the developed best practices at an NCI/FDA/iSBTc sponsored workshop tied to the annual meeting of the iSBTc to be held in Washington DC in the Fall of 2009. This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document.

References

    1. iSBTc iSBTC/FDA Immunotherapy Biomarker Taskforce. 2008.
    1. Atkins MB, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Carbonic anhydrase IX expression predicts outcome in interleukin-2 therapy of renal cancer. Clin Cancer Res. 2005;11:3714–3721. doi: 10.1158/1078-0432.CCR-04-2019.
    1. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek DF, Wang E, Tabak B, Kim DW, De Raffaele G, Pos Z, Marincola FM, Kaufman H. Serum vascular endothelial growth factor (VEGF) and fibronectin predict clinical response to high-dose interleukin-2 (IL-2) therapy. J Clin Oncol. 2008.
    1. Wolchok JD, Chapman PB. How can we tell when cancer vaccines vaccinate? J Clin Oncol. 2003;21:586–587. doi: 10.1200/JCO.2003.12.065.
    1. Panelli MC, Stashower M, Slade HB, Smith K, Norwood C, Abati A, Fetsch P, Filie A, Walters SA, Astry C, Aricó E, Zhao Y, Selleri S, Wang E, Marincola FM. Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol. 2006;8:R8. doi: 10.1186/gb-2007-8-1-r8.
    1. Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C, Wang E, Marincola FM, Stroncek DF. Gene expression profiling of cutaneous wound healing. J Transl Med. 2007;5:11. doi: 10.1186/1479-5876-5-11.
    1. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–213. doi: 10.1056/NEJMoa020177.
    1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi: 10.1126/science.1129139.
    1. Mintzberg H. Organizational design, fashion or fit? Harvard Business Rev. 1981;59:103–116.
    1. Wang E, Marincola FM. A natural history of melanoma: serial gene expression analysis. Immunol Today. 2000;21:619–623. doi: 10.1016/S0167-5699(00)01724-2.
    1. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002;62:3581–3586.
    1. Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA, Klein HG, Marincola FM. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 2002;3:RESEARCH0035. doi: 10.1186/gb-2002-3-7-research0035.
    1. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, Stichweh D, Blankenship D, Li L, Munagala I, Bennett L, Allantaz F, Mejias A, Ardura M, Kaizer E, Monnet L, Allman W, Randall H, Johnson D, Lanier A, Punaro M, Wittkowski KM, White P, Fay J, Klintmalm G, Ramilo O, Palucka AK, Banchereau J, Pascual V. A modular framework for biomarker and knowledge discovery from blood transcriptional profiling studies: application to systemic lupus erythemathosus. Immunity. 2008;29:150–164. doi: 10.1016/j.immuni.2008.05.012.
    1. Wang E, Marincola FM. Bottom up: a modular view of immunology. Immunity. 2008;29:9–11. doi: 10.1016/j.immuni.2008.07.002.
    1. Gabriele L, Moretti F, Pierotti MA, Marincola FM, Foa R, Belardelli F. The use of microarray technologies in clinical oncology. J Transl Med. 2006;4:8. doi: 10.1186/1479-5876-4-8.
    1. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol. 2008;29:256–262. doi: 10.1016/j.it.2008.03.002.
    1. Stroncek DF, Jin P, Wang E, Jett B. Potency analysis of cellular therapies: the emerging role of molecular assays. J Transl Med. 2007;5:24. doi: 10.1186/1479-5876-5-24.
    1. Jin P, Wang E, Ren J, Childs R, Shin JW, Khuu H, Marincola FM, Stroncek DF, et al. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med. 2008;6:39. doi: 10.1186/1479-5876-6-39.
    1. Marks KM, Nolan GP. Chemical labeling strategies for cell biology. Nat Methods. 2006;3:591–596. doi: 10.1038/nmeth906.
    1. Beasley JR, McCoy PM, Walker TL, Dunn DA. Miniaturized, ultra-high throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunoassays. Assay Drug Dev Technol. 2004;2:141–151. doi: 10.1089/154065804323056486.
    1. Rossi L, Martin B, Hortin G, White RLJr, Foster M, Stroncek D, Wang E, Marincola FM, Panelli MC. Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics. 2006;6:709–720. doi: 10.1002/pmic.200500004.
    1. Rossi L, Moharram R, Martin BM, White RL, Panelli MC. Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture. J Transl Med. 2006;4:5. doi: 10.1186/1479-5876-4-5.
    1. Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy N, Phelps ME, Witte ON. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog. Nat Med. 2008;14:783–788. doi: 10.1038/nm1724.
    1. Tumeh PC, Radu CG, Ribas A. PET imaging of cancer immunotherapy. J Nucl Med. 2008;49:865–868. doi: 10.2967/jnumed.108.051342.
    1. Bailey RC, Kwong GA, Radu CG, Witte ON, Heath JR. DNA-encoded antibody libraries: a unified platform for multiplexed cell sorting and detection of genes and proteins. J Am Chem Soc. 2007;129:1959–1967. doi: 10.1021/ja065930i.
    1. Fan R, Vermesh O, Srivastava A, Yen BK, Qin L, Ahmad H, kwong GA, Liu CC, Gould J, Hood L, Heath JR. Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nat Biotechnol. 2008.
    1. Ayache S, Panelli M, Marincola FM, Stroncek DF. Effects of storage time and exogenous protease inhibitors on plasma protein levels. Am J Clin Pathol. 2006;126:174–184. doi: 10.1309/3WM7XJ7RD8BCLNKX.
    1. Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro' V, Smith K, Hu N, Su H, Taylor PR, Marincola FM, Wang E. Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics. 2004;5:55. doi: 10.1186/1471-2164-5-55.
    1. Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanovello P, Freedman RS, Marincola FM. Melanoma-restricted genes. J Transl Med. 2004;2:34. doi: 10.1186/1479-5876-2-34.
    1. Jin P, Wang E, Provenzano M, Deola S, Selleri S, Jiaqiang R, Voiculescu S, Stroncek D, Panelli MC, Marincola FM. Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med. 2006;4:26. doi: 10.1186/1479-5876-4-26.
    1. Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, Taylor PR, Hu N, Zanovello P, Marincola FM, Wang E. Common cancer biomarkers. Cancer Res. 2006;66:2953–2961. doi: 10.1158/0008-5472.CAN-05-3433.
    1. Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J, Xie W, Li Z, Zhao Y, Wang E, Marincola FM, Yao K. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 2008;6:32. doi: 10.1186/1479-5876-6-32.
    1. Maecker HT, Moon J, Bhatia S, Ghanekar SA, Maino VC, Payne JK, Kuus-Reichel K, Chang JC, Summers A, Clay TM, Morse MA, Lyerly HK, DeLaRosa C, Ankerst DP, Disis ML. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol. 2005;6:17. doi: 10.1186/1471-2172-6-17.
    1. Disis ML, dela Rosa C, Goodell V, Kuan LY, Chang JC, Kuus-Reichel K, Clay TM, Kim Lyerly H, Bhatia S, Ghanekar SA, Maino VC, Maecker HT. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods. 2006;308:13–18. doi: 10.1016/j.jim.2005.09.011.
    1. Ghanekar SA, Bhatia S, Ruitenberg JJ, dela RC, Disis ML, Maino VC, Maecker HT, Waters CA. Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors. J Immune Based Ther Vaccines. 2007;5:7. doi: 10.1186/1476-8518-5-7.
    1. Ayache S, Panelli MC, Byrne KM, Slezak S, Leitman SF, Marincola FM, Stroncek DF. Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion. J Transl Med. 2006;4:40. doi: 10.1186/1479-5876-4-40.
    1. Maecker HT, Hassler J, Payne JK, Summers A, Comatas K, Ghanayem M, Morse MA, Clay TM, Lyerly HK, Bhatia S, Ghanekar SA, Maino VC, Delarosa C, Disis ML. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol. 2008;9:9. doi: 10.1186/1471-2172-9-9.
    1. Fraser CG. Biological Variation: from Principles to Practice. Washington, DC: AACCPress; 2001.
    1. Butterfield LH, Gooding W, Whiteside TL. Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother. 2008;31:89–100.
    1. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A, Elispot Proficiency Panel of the CVC Immune Assay Working Group Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) Cancer Immunol Immunother. 2008;57:303–315. doi: 10.1007/s00262-007-0380-6.
    1. Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res. 2006;12:107–116. doi: 10.1158/1078-0432.CCR-05-0136.
    1. Westgard QC: Tools, Technology and Training for Healthcare Laboratories. 2008.
    1. Keilholz U, Weber J, Finke J, Gabrilovich D, Kast WM, Disis N, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB. Immunologic monitoring of cancer vaccine therapy: results of a Workshop sponsored by the Society of Biological Therapy. J Immunother. 2002;25:97–138. doi: 10.1097/00002371-200203000-00001.
    1. Lotze MT, Wang E, Marincola FM, Hanna N, Bugelski PJ, Burns CA, Coukos G, Damle N, Godfrey TE, Howell WM, Panelli MC, Perricone MA, Petricoin EF, Sauter G, Scheibenbogen C, Shivers SC, Taylor DL, Weinstein JN, Whiteside TL. Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients. J Immunother. 2005;28:79–119. doi: 10.1097/01.cji.0000154251.20125.2e.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner